Constitutively released adenosine diphosphate regulates proplatelet formation by human megakaryocytes

Haematologica

Volumn 97, Issue 11, 2012, Pages 1657-1665

  Balduini, Alessandra ^a,b   Di Buduo, Christian Andrea ^a   Malara, Alessandro ^a   Lecchi, Anna ^c   Rebuzzini, Paola ^a   Currao, Manuela ^a   Pallotta, Isabella ^a,b   Jakubowski, Joseph A ^d   Cattaneo, Marco ^c  

^a UNIVERSITY OF PAVIA   (Italy)

^b Tufts University   (United States)

^c UNIVERSITY OF MILAN   (Italy)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

ADP; P2Y13 receptor; Proplatelet formation

Indexed keywords

2 METHYLTHIOADENOSINE 5' MONOPHOSPHATE TRIETHYLAMMONIUM; 2' DEOXY 6 N METHYLADENOSINE 3', 5' BISPHOSPHATE; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; APYRASE; BETA3 INTEGRIN; CANGRELOR; CLOPIDOGREL; MESSENGER RNA; PRASUGREL; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y1 RECEPTOR; PURINERGIC P2Y12 RECEPTOR; PURINERGIC P2Y13 RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MAJOR CLINICAL STUDY; MEGAKARYOCYTE; PHASE CONTRAST MICROSCOPY; PROTEIN EXPRESSION; PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; UMBILICAL CORD BLOOD; WESTERN BLOTTING;

ADENOSINE DIPHOSPHATE; APYRASE; BLOOD PLATELETS; CELLS, CULTURED; FEMALE; FETAL BLOOD; HUMANS; MALE; MEGAKARYOCYTE PROGENITOR CELLS; MEGAKARYOCYTES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2; RECEPTORS, PURINERGIC P2Y1; RECEPTORS, PURINERGIC P2Y12;

EID: 84868556701     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.059212     Document Type: Article

References (40)

1. Avecilla ST, Hattori K, Heissig B, Tejada R, Liao F, Shido K, et al. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med. 2004;10(1):64-71.
2. Italiano JE Jr, Lecine P, Shivdasani RA, Hartwig JH. Blood platelets are assembled principally at the ends of proplatelet processes produced by differentiated megakaryocytes. J Cell Biol. 1999;147(6):1299-312.
3. Youssefian T, Cramer EM. Megakaryocyte dense granule components are sorted in multivesicular bodies. Blood 2000;95(12):4004-7.
4. Richardson JL, Shivdasani RA, Boers C, Hartwig JH, Italiano JE Jr. Mechanisms of organelle transport and capture along proplatelets during platelet production. Blood. 2005;106(13):4066-75.
5. Becker RP, De Bruyn PP. The transmural passage of blood cells into myeloid sinusoids and the entry of platelets into the sinusoidal circulation; a scanning electron microscopic investigation. Am J Anat. 1976;145(2):183-205.
6. Junt, T, Schulze H, Chen Z, Massberg S, Goerge T, Krueger A, et al. Dynamic visualization of thrombopoiesis within bone marrow. Science. 2007;317(5845):1767-70.
7. Thon JN, Montalvo A, Patel-Hett S, Devine MT, Richardson JL, Ehrlicher A, et al. Cytoskeletal mechanics of proplatelet maturation and platelet release. J Cell Biol. 2010;191(4):861-74.
8. Balduini A, Pallotta I, Malara A, Lova P, Pecci A, Viarengo G, et al. Adhesive receptors, extracellular proteins and myosin IIA orchestrate proplatelet formation by human megakaryocytes. J Thromb Haemost. 2008; 6(11):1900-7.
9. Möhle R, Green D, Moore MA, Nachman RL, Rafii S. Constitutive production and thrombin-induced release of vascular growth factor by human megakaryocytes and plateles. Proc Natl Acad Sci USA.1997;94(2):663-8.
10. Casella I, Feccia T, Chelucci C, Samoggia P, Castelli G, Guerriero R, et al. Autocrineparacrine VEGF loops potentiate the maturation of megakaryocytic precursors through Flt1 receptor. Blood. 2003;101(4):1316-23.
11. Thompson CJ, Schilling T, Howard MR, Genever PG. SNARE-dependent glutamate release in megakaryocytes. Exp Hematol. 2010;38(6):504-15.
12. Boeynaems J-M, Communi D, Suarez Gonzales N, Robaye B. Overview of the P2 receptors. Sem Thromb Hemost. 2005;31(2): 139-49.
13. von Kügelen I. Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. Pharmacol Ther. 2006;110(3):415-32.
14. Cattaneo M, Gachet C. ADP receptors and clinical bleeding disorders. Arterioscler Thromb Vasc Biol. 1999;19(10):2281-5.
15. Hechler B, Lenain N, Marchese P, Vial C, Heim V, Freund M, et al. A role of the fast ATP-gated P2X1 cation channel in thrombosis of small arteries in vivo. J Exp Med. 2003;198(4):661-7.
16. Cattaneo M, Lecchi A, Randi AM, McGregor JL, Mannucci PM. Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate. Blood. 1992;80(11):2787-96.
17. Pecci A, Malara A, Badalucco S, Bozzi V, Torti M, Balduini CL, et al. Megakaryocytes of patients with MYH9-related thrombocytopenia present an altered proplatelet formation. Thromb Haemost. 2009;102(1):90-6.
18. Williams N, Levine RF. The origin, development and regulation of megakaryocytes. Br J Haematol. 1982;52(2):173-80.
19. Kaplan LA, Pesce AJ. Clinical Chemistry: Theory, Analysis and Correlation. St. Louis, Missouri: Mosby Ed.; 1996.
20. Malara A, Gruppi C, Rebuzzini P, Visai L, Perotti C, Moratti R, et al. Megakaryocytematrix interaction within bone marrow: new roles for fibronectin and factor XIII-A. Blood. 2011;117(8):2476-83.
21. Dangelmaier CA, Holmsen H. Platelet dense granule and lysosome content. In: Harker LA, Zimmerman TS, eds. Methods in Hematology: Measurement of Platelet Function. Edinburgh, Scotland: Churchill Livingstone; 1983:92-114.
22. Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disese. Eur Heart J. 2006;27(10):1166-73.
23. Marteau F, Le Poul E, Communi D, Communi D, Labouret C, Savi P, et al. Pharmacological characterization of the human P2Y13 receptor. Mol Pharmacol. 2003;64(1):104-12.
24. Fumagalli M, Trincavelli L, Lecca D, Martini C, Ciana P, Abbracchio MP. Cloning, pharmacological characterization and distribution of the rat G-protein-coupled P2Y13 receptor. Biochem Pharmacol. 2004;68(1): 113-24.
25. Wang L, Olivecrona G, Götberg M, Olsson ML, Winzell MS, Erlinge D. ADP acting on P2Y13 receptors is a negative feedback pathway for ATP release from human red blood cells. Circ Res. 2005;96(2):189-96.
26. Kim YC, Lee JS, Sak K, Marteau F, Mamedova L, Boeynaems JM, et al. Synthesis of pyridoxal phosphate derivatives with antagonist activity at the P2Y13 receptor. Biochem Pharmacol. 2005;70(2):266-74.
27. Ortega F, Pérez-Sen R, Miras-Portugal MT. Gi-coupled P2Y-ADP receptor mediates GSK-3 phosphorylation and beta-catenin nuclear translocation in granule neurons. J Neuorchem. 2008; 104(1):62-73.
28. Ortega F, Pérez-Sen R, Delicado EG, Miras-Portugal MT. Erk1/2 activation is involved in the neuroprotecitve action of P2Y13 and P2X7 receptors against glutamate excitotoxicity in cerebellar granule neurons. Neuropharmacology. 2011;61(8):1210-21.
29. Ono M, Matsubara M, Shibano T, Ikeda Y, Murata M. GSK-3 negatively regulates megakaryocyte differentiation and platelet production from primary human bone marrow cells in vitro. Platelets. 2011;22(3):196-203.
30. Jiang F, Jia Y, Cohen I. Fibronectin-and protein kinase C-mediated activation of ERK/MAPK are essential for proplateletlike formation. Blood. 2002;99(10):3579-84.
31. Mazharian A, Watson SP, Séverin S. Critical role for ERK1/2 in bone marrow and fetal liver-derived primary megakaryocyte differentiation, motility, and proplatelet formation. Exp Hematol. 2009;37(10):1238-49.
32. Cattaneo M. Inherited platelet-based bleeding disorders. J Thromb Haemost. 2003;1 (7):1628-36.
33. Weiss HJ, Witte LD, Kaplan KL, Lages BA, Chernoff A, Nossel HL, et al. Heterogeneity in storage pool deficiency: studies on granule-bound substances in 18 patients including variants deficient in alpha-granules, platelet factor 4, beta-thromboglobulin, and platelet-derived growth factor. Blood. 1979; 54(6):1296-319.
34. Nieuwenhuis HK, Akkerman JW, Sixma JJ. Patients with a prolonged bleeding time and normal aggregation tests may have storage pool deficiency: studies on one hundred six patients. Blood. 1987;70(3):620-3.
35. Pujol-Moix N, Hernández A, Escolar G, Español I, Martínez-Brotóns F, Mateo J. Platelet ultrastructural morphometry for diagnosis of partial delta-storage pool disease in patients with mild platelet dysfunction and/or thrombocytopenia of unknown origin. A study of 24 cases. Haematologica. 2000;85(6):619-26.
36. Cattaneo M. The platelet P2Y12 receptor for adenosine diphosphate: congenital and druginduced defects. Blood 2011;117(7):1202-12.
37. Wang L, Jacobsen SE, Bengtsson A, Erlinge D. P2 receptor mRNA expression profiles in human lymphocytes, monocytes and CD34+ stem and progenitor cells. BMC Immunol. 2004;5:16.
38. Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009;361 (24):2330-41.
39. Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009;361 (24):2318-29.
40. Angiolillo DJ, Firstenberg MS, Price MJ, Tummala PE, Hutyra M, Welsby IJ, et al.; BRIDGE Investigators. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA. 2012;307(3):265-74.